Multaq (dronedarone) - Important Safety Information from Sanofi Aventis as approved by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 04/10/2002

 

Problem Or Issue:
The European Medicines Agency's Committee for Medical Products for Human Use (CHMP) has completed its assessment of the benefits and risks of treatment with Multaq (dronedarone).  As a result, the Multaq Summary of Product Characteristics (SmPC) has been modified.  

Sanofi Aventis Multaq DHCP Letter 04.10.11.pdf


« Back